Oncternal Therapeutics, Inc

(NASDAQ:ONCT)

Latest On Oncternal Therapeutics, Inc (ONCT):

Date/Time Type Description Signal Details
2023-05-05 04:00 ESTNewsOncternal Therapeutics GAAP EPS of -$0.20 in-line, revenue of $0.2M beats by $0.06MN/A
2023-05-05 03:59 ESTNewsOncternal Therapeutics, Inc. (ONCT) Q1 2023 Earnings Call TranscriptN/A
2023-05-04 02:39 ESTNewsOncternal Therapeutics Q1 2023 Earnings PreviewN/A
2023-04-04 01:14 ESTNewsOncternal Therapeutics ends two cancer studies, stock craters ~31% after hoursN/A
2023-03-10 11:44 ESTNewsOncternal Therapeutics, Inc. (ONCT) Q4 2022 Earnings Call TranscriptN/A
2023-03-09 20:31 ESTNewsOncternal Therapeutics GAAP EPS of -$0.20 beats by $0.01, revenue of $0.17M misses by $0.11MN/A
2023-01-30 17:17 ESTNewsOncternal Therapeutics: Making Progress And Still In Buy TerritoryN/A
2022-11-04 06:27 ESTNewsOncternal Therapeutics GAAP EPS of -$0.21 beats by $0.03, revenue of $0.38M beats by $0.13MN/A
2022-11-04 06:26 ESTNewsOncternal Therapeutics, Inc. (ONCT) Q3 2022 Earnings Call TranscriptN/A
2022-11-02 21:24 ESTNewsOncternal Therapeutics Q3 2022 Earnings PreviewN/A
2022-10-04 04:47 ESTNewsFDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapyN/A
2022-09-27 15:05 ESTNewsOncternal Therapeutics begins phase 3 study of zilovertamabN/A
2022-09-02 20:04 ESTNewsOncternal Therapeutics: Selling For Under Cash ValueN/A
2022-08-10 03:57 ESTNewsOncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26MN/A
2022-08-10 03:57 ESTNewsOncternal Therapeutics, Inc.'s (ONCT) CEO Dr. James Breitmeyer on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-09 06:07 ESTNewsOncternal Therapeutics Q2 2022 Earnings PreviewN/A
2022-07-15 01:59 ESTNewsOncternal to collaborate with an AbbVie company for its phase 3 lymphoma studyN/A
2022-06-23 17:39 ESTNewsOncternal Therapeutics (ONCT) Investor Presentation -slideshowN/A
2022-06-14 20:33 ESTNewsonctN/A
2022-06-11 05:35 ESTNewsOncternal Therapeutics outlines late-stage study for mantle cell lymphoma candidateN/A
2022-06-07 15:36 ESTNewsOncternal Therapeutics: As Phase 2 Study Matures, Data Continues To ImproveN/A
2022-06-02 12:43 ESTNewsOncternal Therapeutics grants clinical science head options for 70K sharesN/A
2022-05-06 06:02 ESTNewsOncternal Therapeutics GAAP EPS of -$0.20 beats by $0.04, revenue of $0.7M beats by $0.17MN/A
2022-05-06 06:02 ESTNewsOncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-05 07:14 ESTNewsOncternal Therapeutics Q1 2022 Earnings PreviewN/A
2022-04-13 21:02 ESTNewsOncternal deprioritizes development of ONCT-216, to focus on zilovertamab phase 3 trialN/A
2022-03-11 15:46 ESTNewsOncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-10 19:55 ESTNewsOncternal Therapeutics reports Q4 resultsN/A
2022-03-02 04:45 ESTNewsOncternal Therapeutics reports inducement grantsN/A
2022-01-04 16:32 ESTNewsOncternal Therapeutics: Trading Near Cash With Impressive ResultsN/A
2021-11-10 13:18 ESTNewsWarning: ONCT is at high risk of performing badlyN/A
2021-11-05 11:05 ESTNewsOncternal Therapeutics beats on revenueN/A
2021-11-05 11:05 ESTNewsOncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-04 14:00 ESTNewsOncternal Therapeutics Q3 2021 Earnings PreviewN/A
2021-11-02 20:42 ESTNewsOncternal Therapeutics forms Cell Therapy Scientific Advisory BoardN/A
2021-10-12 10:41 ESTNewsWhy I Added Oncternal Therapeutics To My WatchlistN/A
2021-10-10 19:51 ESTNewsOncternal Therapeutics: Keep An Eye On This Biopharmaceutical CompanyN/A
2021-10-06 14:02 ESTNewsOncternal gains 11% ahead of ONCT-534 data presentation at AACR-NCI-EORTC ConferenceN/A
2021-09-22 02:44 ESTNewsOncternal Therapeutics (ONCT) Investor Presentation - SlideshowN/A
2021-08-09 12:28 ESTNewsOncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-06 08:09 ESTNewsOncternal Therapeutics misses on revenueN/A
2021-07-21 18:00 ESTNewsOncternal: Solid Data In 2 Cancers With High Unmet NeedN/A
2021-07-21 17:59 ESTNewsOncternal Therapeutics: New Data Continues To DeriskN/A
2021-07-21 17:53 ESTNewsOncternal Therapeutics names Pablo Urbaneja as Senior VP, Corporate DevelopmentN/A
2021-05-07 13:04 ESTNewsOncternal Therapeutics, Inc. (ONCT) CEO Jim Breitmeyer on Q1 2021 Results - Earnings Call TranscriptN/A
2021-05-06 16:45 ESTNewsOncternal Therapeutics EPS misses by $0.02, misses on revenueN/A
2021-04-18 03:23 ESTNewsAACR 2021 highlights Eli Lilly’s new KRAS battle; Affimed’s Natural Killer cell therapyN/A
2021-04-13 00:04 ESTNewsOncternal Therapeutics down 8% despite promising cirmtuzumab results in broad cancer indicationsN/A
2021-04-07 19:31 ESTNewsFibrogen hurt by downgrades, Emergent earns a bull despite vaccine mix-up and more in today’s analyst actionN/A
2021-04-07 19:31 ESTNewsOppenheimer sees ~62% rise in shares of Oncternal TherapeuticsN/A

About Oncternal Therapeutics, Inc (ONCT):

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. The company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ROR1) that is in Phase I/II clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in Phase Ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. It also develops TK-216, a small-molecule that is designed to inhibit E26 transformation specific family of oncoproteins, which is in Phase I clinical trial to treat patients with Ewing sarcoma and in combination with vincristine chemotherapy. In addition, the company develops a chimeric antigen receptor-T product candidate that targets ROR1, which is in preclinical development for treating hematologic cancers and solid tumors. Oncternal Therapeutics, Inc. has a research and development collaboration with Karolinska Institutet to advance novel ROR1-targeting cell therapies focused on CAR-T cells and CAR-NK cells. The company is headquartered in San Diego, California.

ONCT Quotes by TradingView

See Advanced Chart

General

  • Name Oncternal Therapeutics, Inc
  • Symbol ONCT
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 12
  • Last Split Factor1:7
  • Last Split Date2019-06-10
  • Fiscal Year EndDecember
  • IPO Date2004-02-03
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.oncternal.com
View More

Valuation

  • Trailing PE 2.11
  • Price/Sales (Trailing 12 Mt.) 42.39
  • Price/Book (Most Recent Quarter) 19.79
  • Enterprise Value Revenue 114.85
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.50
  • Next Year EPS Estimate -$1.05
  • Next Quarter EPS Estimate -$0.12
  • Operating Margin -520%
  • Return on Assets -16%
  • Return on Equity -27%
  • Revenue 3.38 million
  • Earnings Per Share -$1.81
  • Revenue Per Share $0.17
  • Gross Profit -9169000
  • Quarterly Earnings Growth 115.8%
View More

Highlights

  • Market Capitalization 436.24 million
  • PE Ratio -0.34
  • Analyst Target Price $15
  • Book Value Per Share $1.18
View More

Share Statistics

  • Shares Outstanding 49.28 million
  • Shares Float 43.48 million
  • % Held by Insiders 2153%
  • % Held by Institutions 17.22%
  • Shares Short 89271
  • Shares Short Prior Month 104119
  • Short Ratio 0.06
View More

Technicals

  • 52 Week High $9.45
  • 52 Week Low $1.49
  • 50 Day Moving Average 6.79
  • 200 Day Moving Average 4.15
View More

Dividends

  • Dividend Date 2019-06-10
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Oncternal Therapeutics, Inc (ONCT) Dividend Calendar:

ONCT's last dividend payment was made to shareholders on June 10, 2019.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Oncternal Therapeutics, Inc (ONCT) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-11$1.59 million-$0.09-$0.1850%
2020-09-302020-11-04$N/A-$0.22-$0.3026.67%
2020-06-302020-08-06$N/A-$0.34-$0.21-61.9%
2020-03-312020-05-07$N/A-$0.31-$0.21-47.62%
2019-12-312020-03-16$736000-$0.27
2019-09-302019-11-07$544000-$0.32
2019-06-302019-08-08$674000-$3.38
2019-03-312019-05-10$572000-$1.69
2018-12-312019-03-18$N/A-$0.22-$0.21-4.76%
2018-09-302018-10-22$329000-$0.39-$0.30-30%
2018-06-302018-08-14$1.53 million-$0.43-$0.430%
2018-03-312018-05-15$857500-$0.62-$0.43-44.19%
2017-12-312018-03-12$N/A-$0.43-$0.4810.42%
2017-09-302017-11-14$N/A-$0.53-$0.28-89.29%
2017-06-302017-08-14$N/A-$2.79
2017-03-312017-05-15$N/A-$2.73
2016-12-312017-03-15$N/A-$0.44-$0.5722.81%
2016-09-302016-11-03$N/A-$0.50-$0.500%
2016-06-302016-08-09$N/A-$0.40-$0.5020%
2016-03-312016-05-10$N/A$0.10-$0.40125%
2015-12-312016-03-03$N/A-$0.40-$1.0060%
2015-09-302015-10-29$N/A-$0.40-$0.6033.33%
2015-06-302015-08-06$N/A-$3.40-$0.40-750%
2015-03-312015-05-08$N/A-$0.20-$0.4050%
2014-12-312015-03-04$N/A-$0.50-$0.9547.37%
2014-09-302014-11-10$N/A-$0.06-$0.1145.45%
2014-06-302014-08-05$N/A-$1.50-$1.18-27.12%
2014-03-312014-05-08$N/A-$1.40-$1.16-20.69%
2013-12-312014-03-04$N/A-$1.20-$1.307.69%
2013-09-302013-11-12$N/A-$1.40-$2.1233.96%
2013-06-302013-07-19$N/A-$2.00-$2.188.26%
2013-03-312013-05-03$N/A-$2.00-$2.083.85%
2012-12-312013-02-21$N/A-$1.70-$2.1420.56%
2012-09-302012-11-08$N/A-$0.80-$1.8256.04%
2012-06-302012-08-08$1.64 million-$1.70-$1.67-1.8%
2012-03-312012-05-08$1.83 million-$1.80-$1.62-11.11%
2011-12-312012-02-21-$1.70-$1.67-1.8%
2011-09-302011-11-04$2.03 million-$1.50-$1.8318.03%
2011-06-302011-08-09$1.65 million-$2.10-$1.84-14.13%
2011-03-312011-05-09-$0.50-$1.3262.12%
2010-12-312011-02-24-$1.60-$1.621.23%
2010-09-302010-11-09-$2.40-$2.8816.67%
2010-06-302010-08-09-$3.60-$2.74-31.39%
2010-03-312010-05-04$12.20$11.724.1%
2009-12-312010-03-15-$3.00-$3.5315.01%
2009-09-302009-11-09-$3.50-$3.43-2.04%
2009-06-302009-08-10-$3.10-$3.6214.36%
2009-03-312009-05-11-$3.10-$3.8018.42%
2008-12-312009-02-17-$3.80-$3.882.06%
2008-09-302008-11-06-$3.30-$4.2021.43%
2008-06-302008-08-05-$3.70-$3.771.86%
2008-03-312008-05-12-$3.50-$3.00-16.67%
2007-12-312008-02-19-$3.60-$3.36-7.14%
2007-09-302007-11-06-$2.90-$3.5818.99%
2007-06-302007-07-31-$2.60-$3.3021.21%
2007-03-312007-05-04-$2.30-$2.8419.01%
2006-12-312007-02-20-$1.50-$3.5257.39%
2006-09-302006-11-02-$3.50-$3.541.13%
2006-06-302006-07-27-$3.20-$3.457.25%
2006-03-312006-04-27-$3.20-$3.15-1.59%
2005-12-312006-02-16-$2.60-$3.5025.71%
2005-09-302005-11-03-$4.00-$4.409.09%
2005-06-302005-07-28-$4.10-$4.100%
2005-03-312005-04-28-$3.70-$3.65-1.37%
2004-12-312005-02-16-$2.80-$3.078.79%
2004-09-302004-11-11-$2.10-$3.0230.46%
2004-06-302004-07-29-$1.80-$2.7735.02%
2004-03-312004-04-19-$2.60-$2.838.13%
2003-12-312004-02-16-$140.96

Oncternal Therapeutics, Inc (ONCT) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Oncternal Therapeutics, Inc (ONCT) Chart:

Oncternal Therapeutics, Inc (ONCT) News:

Below you will find a list of latest news for Oncternal Therapeutics, Inc (ONCT) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Oncternal Therapeutics, Inc (ONCT) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest ONCT Trades:

Date Shares Price
Jun 13, 2022 7:55 PM EST100$1.105
Jun 13, 2022 7:57 PM EST100$1.105
Jun 13, 2022 7:57 PM EST100$1.105
Jun 13, 2022 7:59 PM EST100$1.105
Jun 13, 2022 7:59 PM EST100$1.105

Oncternal Therapeutics, Inc (ONCT) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000119312520183364/0001193125-20-183364-index.htm
2020-07-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000089924320020208/0000899243-20-020208-index.htm
2020-07-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000089924320020210/0000899243-20-020210-index.htm
2020-09-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000089924320023996/0000899243-20-023996-index.htm
2020-05-29SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1260990/000091957420003886/0000919574-20-003886-index.htm
2014-03-05DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1600987/000114036114011051/0001140361-14-011051-index.htm
2015-08-07DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1600987/000114036115030436/0001140361-15-030436-index.htm
2016-03-10D/ANotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1600987/000114036116057332/0001140361-16-057332-index.htm
2016-06-08DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1600987/000114036116069073/0001140361-16-069073-index.htm
2016-07-08DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1600987/000114036116071979/0001140361-16-071979-index.htm
2016-10-20D/ANotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1600987/000114036116083095/0001140361-16-083095-index.htm
2016-12-09D/ANotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1600987/000114036116089151/0001140361-16-089151-index.htm
2017-03-23D/ANotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1600987/000114036117013027/0001140361-17-013027-index.htm
2017-09-27DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1600987/000114036117036629/0001140361-17-036629-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1260990/000119312520038163/0001193125-20-038163-index.htm
2020-05-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1260990/000119312520148008/0001193125-20-148008-index.htm
2020-06-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000119312520183364/0001193125-20-183364-index.htm
2020-07-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1260990/000119312520195818/0001193125-20-195818-index.htm
2020-07-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000119312520196296/0001193125-20-196296-index.htm
2020-07-23SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1260990/000119312520197825/0001193125-20-197825-index.htm
2020-08-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000119312520233183/0001193125-20-233183-index.htm
2020-08-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1260990/000119312520233290/0001193125-20-233290-index.htm
2020-08-27FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1260990/000119312520233294/0001193125-20-233294-index.htm
2020-08-28FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1260990/000119312520233442/0001193125-20-233442-index.htm
2020-08-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1260990/000119312520234873/0001193125-20-234873-index.htm
2020-08-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000119312520236278/0001193125-20-236278-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919119049691/0001209191-19-049691-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919119049692/0001209191-19-049692-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919119049693/0001209191-19-049693-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919119049695/0001209191-19-049695-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919119049696/0001209191-19-049696-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919119049697/0001209191-19-049697-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919119049698/0001209191-19-049698-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919119061668/0001209191-19-061668-index.htm
2019-12-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919119061669/0001209191-19-061669-index.htm
2020-01-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120002701/0001209191-20-002701-index.htm
2020-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120020087/0001209191-20-020087-index.htm
2020-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120020088/0001209191-20-020088-index.htm
2020-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120020090/0001209191-20-020090-index.htm
2020-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120020091/0001209191-20-020091-index.htm
2020-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120020092/0001209191-20-020092-index.htm
2020-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120020095/0001209191-20-020095-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120031792/0001209191-20-031792-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120036297/0001209191-20-036297-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120036299/0001209191-20-036299-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120036300/0001209191-20-036300-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120036302/0001209191-20-036302-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120036304/0001209191-20-036304-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120036306/0001209191-20-036306-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120036307/0001209191-20-036307-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120036309/0001209191-20-036309-index.htm
2020-07-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120043496/0001209191-20-043496-index.htm
2020-07-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120043497/0001209191-20-043497-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044354/0001209191-20-044354-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044355/0001209191-20-044355-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044356/0001209191-20-044356-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044357/0001209191-20-044357-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044358/0001209191-20-044358-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044359/0001209191-20-044359-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044360/0001209191-20-044360-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044361/0001209191-20-044361-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044362/0001209191-20-044362-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044363/0001209191-20-044363-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044364/0001209191-20-044364-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044365/0001209191-20-044365-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044366/0001209191-20-044366-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044367/0001209191-20-044367-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044368/0001209191-20-044368-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044369/0001209191-20-044369-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044372/0001209191-20-044372-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044373/0001209191-20-044373-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044374/0001209191-20-044374-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044375/0001209191-20-044375-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044376/0001209191-20-044376-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044377/0001209191-20-044377-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044378/0001209191-20-044378-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044379/0001209191-20-044379-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044380/0001209191-20-044380-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044381/0001209191-20-044381-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044382/0001209191-20-044382-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044383/0001209191-20-044383-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044384/0001209191-20-044384-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044385/0001209191-20-044385-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044386/0001209191-20-044386-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044387/0001209191-20-044387-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044388/0001209191-20-044388-index.htm
2020-07-314/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000120919120044389/0001209191-20-044389-index.htm
2019-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000156459019034816/0001564590-19-034816-index.htm
2019-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000156459019036314/0001564590-19-036314-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000156459019041847/0001564590-19-041847-index.htm
2019-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1260990/000156459019041983/0001564590-19-041983-index.htm
2019-12-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000156459019045493/0001564590-19-045493-index.htm
2019-12-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000156459019045870/0001564590-19-045870-index.htm
2019-12-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000156459019046603/0001564590-19-046603-index.htm
2019-12-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000156459019047260/0001564590-19-047260-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000156459020000836/0001564590-20-000836-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000156459020011164/0001564590-20-011164-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1260990/000156459020011213/0001564590-20-011213-index.htm
2020-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000156459020011614/0001564590-20-011614-index.htm
2020-04-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000156459020014845/0001564590-20-014845-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1260990/000156459020019683/0001564590-20-019683-index.htm
2020-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1260990/000156459020019695/0001564590-20-019695-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000156459020022295/0001564590-20-022295-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1260990/000156459020022300/0001564590-20-022300-index.htm
2020-05-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000156459020026061/0001564590-20-026061-index.htm
2020-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000156459020026567/0001564590-20-026567-index.htm
2020-06-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000156459020029385/0001564590-20-029385-index.htm
2020-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000156459020035200/0001564590-20-035200-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000156459020037774/0001564590-20-037774-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1260990/000156459020037842/0001564590-20-037842-index.htm
2020-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1260990/000156459020050562/0001564590-20-050562-index.htm
2020-11-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1260990/000156459020050576/0001564590-20-050576-index.htm
2018-11-21DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1600987/000156761918006807/0001567619-18-006807-index.htm
2020-06-03DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000156761920011596/0001567619-20-011596-index.htm
2020-08-03DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000156761920013993/0001567619-20-013993-index.htm
2020-09-09DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1260990/000156761920016587/0001567619-20-016587-index.htm

Oncternal Therapeutics, Inc (ONCT) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Oncternal Therapeutics, Inc (ONCT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2153%
Institutional Ownership: 1722%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-07-21DANIEL L KISNERDirectorBuy10,000.002.3823,825.0010,000.00https://www.sec.gov/Archives/edgar/data/1260990/000120919120043497/0001209191-20-043497-index.htm
2020-07-21Shanghai Pharmaceutical (USA) Inc.10% Share HolderBuy1,049,317.002.382,499,997.753,544,431.00https://www.sec.gov/Archives/edgar/data/1260990/000089924320020210/0000899243-20-020210-index.htm
2020-07-21HAZEL M AKERLegal CounselBuy41,972.002.3899,998.2946,987.00https://www.sec.gov/Archives/edgar/data/1260990/000120919120043496/0001209191-20-043496-index.htm
2020-05-21DAVID F HALEDirectorBuy17,412.00716,818.00https://www.sec.gov/Archives/edgar/data/1260990/000120919120031792/0001209191-20-031792-index.htm
2020-09-01MICHAEL G CARTERDirectorBuy71,429.002.10150,000.9071,947.00https://www.sec.gov/Archives/edgar/data/1260990/000089924320023996/0000899243-20-023996-index.htm